- Home
- DGICA vs GERN Comparison
DGICA vs GERN Comparison
Compare DGICA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICA | GERN |
|---|---|---|
| Founded | 1986 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.0M | 753.3M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | DGICA | GERN |
|---|---|---|
| Price | $20.43 | $1.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $18.00 | $3.00 |
| AVG Volume (30 Days) | 118.3K | ★ 7.1M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ 219.91 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $987,826,105.00 | $183,403,000.00 |
| Revenue This Year | $2.26 | $147.34 |
| Revenue Next Year | $3.46 | $39.11 |
| P/E Ratio | $8.62 | ★ N/A |
| Revenue Growth | 0.89 | ★ 522.13 |
| 52 Week Low | $14.17 | $1.04 |
| 52 Week High | $21.12 | $3.80 |
Technical Indicators
Market Signals| Indicator | DGICA | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 59.40 |
| Support Level | $19.40 | $1.30 |
| Resistance Level | $21.06 | $1.45 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 62.78 | 66.67 |
Price Performance
Historical ComparisonAbout DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.